VivoSeq
Other

Ascorbic Acid

0

Pipeline Programs

0

Active Trials

1

Companies Involved

Ascorbic Acid is an early-stage landscape with 0 programs across 1 company. The most active players are McGuff Pharmaceuticals, Inc..

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

18

clinical trials

Completed14 · 78%
Withdrawn2 · 11%
Unknown status2 · 11%

Trial Activity

18 trials

High Dose Ascorbic Acid Treatment of CMT1A
Completed·WWayne State University·Phase 2/3·NCT00484510·110 enrolled
Ascorbic Acid Treatment in CMT1A Trial (AATIC)
Completed··Phase 2·NCT00271635·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)